107 related articles for article (PubMed ID: 19681063)
21. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis.
Rodríguez-Ferrero M; Ampuero J; Anaya F
Transplant Proc; 2009; 41(6):2406-8. PubMed ID: 19715934
[TBL] [Abstract][Full Text] [Related]
22. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
23. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation.
Dello Strologo L; Guzzo I; Laurenzi C; Vivarelli M; Parodi A; Barbano G; Camilla R; Scozzola F; Amore A; Ginevri F; Murer L
Transplantation; 2009 Aug; 88(3):417-20. PubMed ID: 19667947
[TBL] [Abstract][Full Text] [Related]
24. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome.
Nozu K; Iijima K; Fujisawa M; Nakagawa A; Yoshikawa N; Matsuo M
Pediatr Nephrol; 2005 Nov; 20(11):1660-3. PubMed ID: 16133051
[TBL] [Abstract][Full Text] [Related]
25. Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion.
Sato M; Kamei K; Ogura M; Ishikura K; Ito S
Clin Exp Nephrol; 2018 Feb; 22(1):110-116. PubMed ID: 28434126
[TBL] [Abstract][Full Text] [Related]
26. Rituximab dose-escalation trial in chronic lymphocytic leukemia.
O'Brien SM; Kantarjian H; Thomas DA; Giles FJ; Freireich EJ; Cortes J; Lerner S; Keating MJ
J Clin Oncol; 2001 Apr; 19(8):2165-70. PubMed ID: 11304768
[TBL] [Abstract][Full Text] [Related]
27. Rituximab efficiency in children with steroid-dependent nephrotic syndrome.
Sellier-Leclerc AL; Macher MA; Loirat C; Guérin V; Watier H; Peuchmaur M; Baudouin V; Deschênes G
Pediatr Nephrol; 2010 Jun; 25(6):1109-15. PubMed ID: 20238230
[TBL] [Abstract][Full Text] [Related]
28. Recurrent fevers, cough, and pulmonary opacities in a middle-aged man.
Bauer PR; Zent CS; Aubry MC; Ryu JH
Chest; 2010 Jun; 137(6):1465-9. PubMed ID: 20525658
[No Abstract] [Full Text] [Related]
29. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome.
Marie I; Dominique S; Janvresse A; Levesque H; Menard JF
Respir Med; 2012 Apr; 106(4):581-7. PubMed ID: 22280877
[TBL] [Abstract][Full Text] [Related]
30. High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Radin M; Barreca A; Fenoglio R; Baldovino S; Menegatti E
Am J Nephrol; 2017; 46(2):108-113. PubMed ID: 28700988
[TBL] [Abstract][Full Text] [Related]
31. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
32. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
[TBL] [Abstract][Full Text] [Related]
33. Ofatumumab-associated acute pneumonitis: Not new but still the first case.
Bonanni A; Bertelli E; Panicucci C; D'Alessandro M; Moscatelli A; Lampugnani E; Sacco O; Magnano GM; Ravani P; Ghiggeri GM
Pharmacol Res Perspect; 2017 Feb; 5(1):e00267. PubMed ID: 28596831
[TBL] [Abstract][Full Text] [Related]
34. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
Huang J; Du J; Wang S; Xiao L; Zhao X
Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
[TBL] [Abstract][Full Text] [Related]
36. Development of psoriasis after B cell depletion with rituximab.
Dass S; Vital EM; Emery P
Arthritis Rheum; 2007 Aug; 56(8):2715-8. PubMed ID: 17665440
[TBL] [Abstract][Full Text] [Related]
37. Rituximab in anti-GBM disease: A retrospective study of 8 patients.
Touzot M; Poisson J; Faguer S; Ribes D; Cohen P; Geffray L; Anguel N; François H; Karras A; Cacoub P; Durrbach A; Saadoun D
J Autoimmun; 2015 Jun; 60():74-9. PubMed ID: 25953709
[TBL] [Abstract][Full Text] [Related]
38. [Interstitial pneumonitis as a side effect of rituximab].
Kemming JL; van Zeeland RE; Ullmann EF; Mattijssen EJ
Ned Tijdschr Geneeskd; 2009; 153():A526. PubMed ID: 19785875
[TBL] [Abstract][Full Text] [Related]
39. Rituximab in treatment of idiopathic glomerulopathy.
El-Reshaid K; Sallam HT; Hakim AA; Al-Attiyah R
Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):973-8. PubMed ID: 22982909
[TBL] [Abstract][Full Text] [Related]
40. Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?
Dötsch J; Müller-Wiefel DE; Kemper MJ
Pediatr Nephrol; 2008 Jan; 23(1):3-7. PubMed ID: 17899207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
